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Summary
The inhibition of butyrylcholinesterase (BChE, EC 3.1.1.8) appears to be of interest in
treating diseases with symptoms of reduced neurotransmitter levels, such as Alzheimer’s
disease. However, BCHE gene polymorphism should not be neglected in research since it
could have an effect on the expected outcome. Several well-known cholinergic drugs (e.g.
galantamine, huperzine and rivastigmine) originating from plants, or synthesised as deriva-
tives of plant compounds, have shown that herbs could serve as a source of novel target-
-directed compounds. We focused our research on flavonoids, biologically active polyphe-
nolic compounds found in many plants and plant-derived products, as BChE inhibitors.
All of the tested flavonoids: galangin, quercetin, fisetin and luteolin reversibly inhibited
usual, atypical, and fluoride-resistant variants of human BChE. The inhibition potency in-
creased in the following order, identically for all three BChE variants: luteolin<fisetin<
quercetin<galangin. The determined enzyme-inhibitor dissociation constants (Ki) ranged
from 10 to 170 mmol/L. We showed that no significant change in the inhibition potency of
selected flavonoids exists in view of BChE polymorphism. Our results suggested that fla-
vonoids could assist the further development of new BChE-targeted drugs for treating
symptoms of neurodegenerative diseases and dementia.
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Introduction
Flavonoids, which belong to a large family of bio-
logically active polyphenolic compounds, are found in
many plants and plant-derived products that are com-
ponents of the everyday human diet (fruits, vegetables,
chocolates, herbs, red wine, tea, beer, etc.). A large num-
ber of effects have been attributed to flavonoids, but the
most common activity observed for almost all of these
substances is potent antioxidant and free-radical scaveng-
ing (1,2). Also, flavonoids are capable of modulating gene
expression (3) and the activity of many enzymes includ-
ing tyrosine- and cyclin-dependent kinases (CDKs) (4,5).
Furthermore, many enzymes possess a high affinity to-
wards binding flavonoids (6), while the subgroup of fla-
vonoids known as phytoestrogens, which shares a simi-
lar chemical structure to estrogens, is reported to improve
cognitive function in Alzheimer’s disease patients (7). In-
deed, today’s neurodegenerative disease therapy is based
on acetylcholinesterase (AChE) inhibitors (e.g. galanta-
mine, huperzine and rivastigmine) which originate from
plants, or are synthesised as derivatives of plant com-
pounds, suggesting that herbs could potentially serve as
sources for novel therapeutics (8,9).
Recently, we have evaluated flavonoid interactions
with butyrylcholinesterase (BChE; EC 3.1.1.8) focusing on
the structural aspects of BChE inhibition (10). Although
the physiological function of BChE remains unclear, BChE
serves as a co-regulator of cholinergic neurotransmission
because it can efficiently hydrolyse the neurotransmitter
acetylcholine (11,12), which is primarily the role of AChE.
Therefore, the inhibition of BChE may have a consider-
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able part in treating symptoms of neurodegenerative
diseases and dementia (13) characterised by reduced
acetylcholine concentration. However, the efficacy of any
drug that targets BChE activity can be affected by human
BCHE gene polymorphism. Namely, 66 mutations of the
BCHE gene have been identified to date (14), and several
BChE variants possess different catalytic properties or
are expressed at lower levels than usual BChE (15,16).
For example, people with atypical BChE are unable to
hydrolyse the muscle relaxant succinylcholine and can
experience prolonged apnoea if this relaxant is adminis-
tered (17). The most frequent atypical and fluoride-resis-
tant human BChE variants can be distinguished from the
usual BChE by the lower degree of inhibition by dibu-
caine, sodium fluoride and dimethylcarbamate Ro 02-
-0683 (18,19). The atypical variant carries BCHE muta-
tion D70G, while the fluoride-resistant variant carries
mutations T243M or G390V. The positions affected by
these mutations are far from the active site and are not
directly involved in the catalysis. However, they could
affect the inhibition selectivity of some ligands (20,21) or
the cholinesterase stereoselectivity in interaction with
chiral compounds (22).
In this study, we have evaluated the inhibition of
human BChE variants, usual, atypical and fluoride-resis-
tant, by four flavonoids: galangin, quercetin, fisetin (fla-
vonols), and luteolin (flavon). These flavonoids were
chosen based on our recent study on human BChE and
AChE inhibition (8). The aim of this study is to establish




The studied flavonoids (Fig. 1) (Sigma-Aldrich Co.,
St. Louis, MO, USA) were a gift from Dr. Dubravko Jeli}
(Fidelta Co., Zagreb, Croatia) and Prof. Gordana Rusak
(Faculty of Science, Univesity of Zagreb, Zagreb, Croatia).
Propionylthiocholine iodide (PTCh) and 5,5´-dithiobis-
(2-nitrobenzoic acid) (DTNB) were purchased from Sigma-
-Aldrich Co. Stock solutions (10–100 mM) were prepared
in DMSO (galangin), while quercetin, fisetin and luteolin
were disolved in 96 % ethanol. PTCh stock solution (10
mM) was prepared in water, while DTNB was prepared
in 0.1 M sodium phosphate buffer (pH=7.4). The solu-
tions of all compounds were prepared immediately prior
to use.
Enzymes
The source of BChE was the native human serum.
Specimens of the fluoride-resistant BChE variant were pro-
vided by Dr. Robert T. Evans (Cholinesterase Investiga-
tion Unit at St. James’s University Hospital, Leeds, UK)
and specimens of the atypical BChE variant by Dr. Ok-
sana Lockridge (University of Nebraska Medical Center,
Eppley Institute, Omaha, NE, USA). The determination
of BChE variants was carried out earlier by measuring
the percentage of inhibition by dibucaine, sodium fluor-
ide and Ro 02-0683 (18,19). Final serum dilution was 100-
-fold.
Enzyme activity measurements
The enzyme activity was measured with PTCh as a
substrate in 0.1 M sodium phosphate buffer, pH=7.4,
using the modified Ellman spectrophotometric method
(23,24) with DTNB as the thiol reagent (final concentra-
tion of 0.30 mM). Measurements were carried out at 25
°C and 412 nm using the Cary 300 spectrophotometer
with a temperature controller (Varian Inc., Mulgrave, Vic-
toria, Australia).
Enzyme inhibition
The reversible inhibition of BChE by flavonoids was
measured by determining the decrease of enzyme activi-
ty towards PTCh (0.05–1.0 mM) in the presence of flavo-
noids. The reaction mixture contained BChE suspended
in the phosphate buffer, DTNB, flavonoid and PTCh. To
avoid its instability in the buffer, the flavonoid was add-
ed to the mixture immediately prior to starting the en-
zyme reaction with the substrate PTCh. At least three
different concentrations of flavonoids (Table 1) for each
substrate concentration were used in at least two experi-
ments. All of the possible side-reactions of the enzyme
with DMSO and ethanol, or PTCh with DMSO, ethanol
and flavonoids were negligible.
The dissociation constants of the enzyme-flavonoid
complex (Ki) describing the reversible inhibition by fla-
vonoids were determined as described previously (8,20).
The determination of kinetic constants was carried out
using the GraphPadPrism program (GraphPad Software,
Inc., La Jolla, CA, USA).
Results and Discussion
All four selected flavonoids (galangin, quercetin, fise-
tin, and luteolin; Fig. 1) reversibly inhibited the tested
BChE variants. Experimentally determined flavonoid-en-
zyme dissociation inhibition constants (Ki) ranged from
5 to 200 mmol/L (Table 1). The inhibition potency in-
creased in the following order for all of the BChE vari-
ants: luteolin<fisetin<quercetin<galangin.
The atypical BChE was indistinguishable from the
usual BChE after the inhibition with all four flavonoids,
which is probably the consequence of the neutral charge
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Fig. 1. Chemical structure of the tested flavonoids
of flavonoids since it is known that mutation in the aty-
pical variant (D70G) reduces the inhibition potency of
many charged ligands and BChE inhibitors (19,20,25,26).
However, in the case of galangin and quercetin, the fluor-
ide-resistant variant slightly differed from the usual BChE.
Galangin was three times less potent as an inhibitor of
the fluoride-resistant variant than as an inhibitor of the
usual BChE, and the inhibition was non-competitive since
it was characterised by a substrate concentration-inde-
pendent inhibition. On the other hand, quercetin inhi-
bition potency slightly increased compared to the usual
BChE. These changes could be attributed to the fluoride-
-resistant variant mutations T243M or G390V which, even
when far from the enzyme active centre, could cause
conformational changes resulting in the change of flavo-
noid interaction within the BChE active site.
In a previous study, we attributed flavonoid potency
for inhibiting usual BChE to the number of OH groups
and their side of the phenyl ring or perhaps to the lack
of a C-8 hydroxyl group (8), which can also be asserted
for the atypical and fluoride-resistant variants. A dock-
ing study showed that flavonoids bind to the BChE ac-
tive site by forming multiple residue p-p interactions and
hydrogen bonds (8). Since all aromatic residues within
the BChE active site of atypical and fluoride-resistant
variants are identical, there is no change in the flavonoid
interactions and the inhibition potency between the most
frequent variants of BChE.
Together with previous studies, the results present-
ed here suggest that flavonoids could assist further de-
velopment of new active drugs for treating symptoms of
neurodegenerative diseases and dementia (8,27). In our
opinion, the most promising candidate is the flavonol ga-
langin, a major flavonoid found in the rhizome of Alpi-
nia officinarum (27), due to its binding selectivity, charac-
terised by a ratio of inhibition between BChE and AChE,
which was particularly noticeable in the case of usual
BChE (a 12 times higher preference for binding to BChE
than to AChE) (8). The selectivity was only slightly de-
creased for the fluoride-resistant BChE variant. Further-
more, apart from its antioxidant and free-radical scav-
enging activity, galangin is capable of modulating the
hypoxia-induced factor (28). Nevertheless, the research
in the field of flavonoids as cholinesterase inhibitors is
becoming more and more interesting as new data are
being published (29). For example, this recent study by
Cho et al. (29) points out several geranylated flavonoids
isolated from Paulownia tomentosa fruits as potent cholin-
esterase inhibitors (in mM range), more potent than their
ungeranylated parent compounds.
However, developing flavonoids as plant-derived
drugs still presents a challenge, as their bioavailability is
a major concern, especially with regard to oral admini-
stration. Flavonoids are synthesised in plants mainly as
glycosides and it has been established that bound sugars
are of great importance for compound absorption from the
gastrointestinal tract (30). Furthermore, flavonoid circu-
lation in the blood is relatively short as they are quickly
metabolized and secreted. On the other hand, flavonoids
possess lower toxicity compared to other compounds that
originate from plants (such as alkaloids) and are able to
cross the blood-brain barrier. These facts make a strong
case in favour of flavonoids as drugs acting on specific
targets during treatment of neurodegenerative diseases
(31,32).
Conclusion
Flavonoids as natural compounds present a great po-
tential to protect against a variety of human diseases, par-
ticularly cardiovascular diseases and cancer. BChE is in-
volved in the metabolism of various drugs, toxins, and
synthetic poisons and its inhibition may have a consi-
derable role in treating neurodegenerative diseases. How-
ever, its activity can be affected by BCHE gene polymor-
phism. We have shown that quercetin, galangin, fisetin
and luteolin are equally potent reversible inhibitors of
the usual, atypical and fluoride-resistant variants of BChE.
The most potent inhibitor of all three variants, galangin,
could be a promising lead in the search for new BChE
inhibitors.
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